Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.85) per share. This is a 90.51 percent increase over losses of $(8.96) per share from the same period last year.
HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $57 price target.